About Central Sleep Apnoea (CSA)
Central Sleep Apnoea (CSA) is a type of sleep-disordered breathing. Unlike Obstructive Sleep Apnoea (OSA) patients who have partially or fully blocked upper airways that restrict breathing, patients with CSA have a lack of respiratory drive. This means either the breathing centre in the brain fails to trigger breathing, or the signal to inhale is not transmitted properly to the rest of the patient’s body.
It can be challenging to treat patients with CSA, who often experience less or different symptoms than OSA patients. Adaptive servo-ventilation (ASV)* featured in AirCurveTM 10 CS PaceWaveTM is an appropriate choice for treating most of these more complex patients.
1.5% of OSA patients suffer from CompSA.1
Up to 45% of patients on opioids for chronic pain suffer from CSA or CompSA.2
5-12% of ischemic and hemorrhagic stroke and transient ischemic attack (TIA) patients suffer from primarily central apnoeas.3
Treatment of CSA
Compared to other forms of PAP therapy, ASV offers significant benefits for the treatment of central SDB.
SERVE-HF has become a key study in its field, contributing significantly to ASV clinical practice.
Other ASV studies
ResMed remains committed to ASV and to exploring both conventional and innovative forms of research.
* ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.